A5048889661- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Infective Endocarditis Diagnosis and Management
- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrest and Resuscitation
- Cardiac, Anesthesia and Surgical Outcomes
- Coronary Interventions and Diagnostics
- Heart Failure Treatment and Management
- Aortic Disease and Treatment Approaches
- Trauma and Emergency Care Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Central Venous Catheters and Hemodialysis
- Membrane-based Ion Separation Techniques
- Potassium and Related Disorders
- Lipoproteins and Cardiovascular Health
- Disaster Response and Management
- Aortic aneurysm repair treatments
- Renal and Vascular Pathologies
- Fuel Cells and Related Materials
- Cardiac Imaging and Diagnostics
- Diagnosis and Treatment of Venous Diseases
- Cardiac pacing and defibrillation studies
- Traumatic Brain Injury Research
Saint Luke's Hospital
2015-2025
University of Missouri–Kansas City
2014-2025
Cardiovascular Research Foundation
2023
MedStar Health
2017
Columbia University Irving Medical Center
2017
Vanderbilt University Medical Center
2017
Duke Medical Center
2017
Valve (United States)
2017
Clinical Research Institute
2017
Duke University Hospital
2017
In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects patients obesity-related heart failure preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and could modify dose.
In the Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms, physical limitations, exercise function, reduced bodyweight patients obesity-related preserved ejection fraction (HFpEF). Whether improves functional status, as assessed by NYHA class, is unknown.
More women than men have heart failure with preserved ejection fraction (HFpEF).
Background— The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated that in patients with 3-vessel or left main coronary artery disease, bypass graft surgery (CABG) was associated a lower rate of cardiovascular death, myocardial infarction, stroke, repeat revascularization compared percutaneous drug-eluting stents (DES-PCI)). long-term cost-effectiveness these strategies is unknown. Methods Results— 2005 2007, 1800 disease were...
Background: In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter valve replacement (TAVR) the SAPIEN 3 has been shown to reduce composite of death, stroke, or rehospitalization 2-year follow-up compared (SAVR). Whether TAVR is cost-effective SAVR for low-risk remains uncertain. Methods: Between 2016 and 2017, 1000 were randomly assigned in PARTNER trial (Placement Aortic Transcatheter Valves). Of these patients, 929 underwent replacement,...
After aortic valve replacement, left ventricular afterload is often characterized by the residual obstruction. Our objective was to determine whether higher systemic arterial afterload-as reflected in blood pressure, pulsatile and resistive load-is associated with adverse clinical outcomes after transcatheter replacement (TAVR).Total, pulsatile, load were measured 2141 patients severe stenosis treated TAVR PARTNER I trial (Placement of Aortic Transcatheter Valve) who had systolic pressure...
Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for suboptimal use of MRA.
Background: The 3M-TAVR trial (3M-Transcatheter Aortic Valve Replacement) demonstrated the feasibility and safety of next-day hospital discharge after transfemoral TAVR with implementation a minimalist pathway. However, economic impact this approach is unknown. Therefore, we evaluated costs for patients undergoing compared conventional TAVR. Methods: We used propensity matching to compare resource utilization (from US health care system perspective) in those enrolled contemporaneous S3i...
Background: In patients with acute deep vein thrombosis (DVT), pharmacomechanical catheter-directed thrombolysis (PCDT) in conjunction anticoagulation therapy is increasingly used the goal of preventing postthrombotic syndrome. Long-term costs and cost-effectiveness these 2 treatment strategies from perspective US healthcare system have not been compared. Methods Results: Between 2009 2014, ATTRACT trial (Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed...
<h3>Importance</h3> In the CoreValve High-Risk Trial, patients with severe symptomatic aortic stenosis had similar clinical outcomes transcatheter valve replacement (TAVR) vs surgical (SAVR) over 5 years of follow-up, mortality rates more than 50% in both groups. <h3>Objective</h3> To describe long-term health status surviving randomized to self-expanding TAVR SAVR. <h3>Design, Setting, and Participants</h3> This trial included at high risk who completed a baseline Kansas City Cardiomyopathy...
Ezetimibe, when added to simvastatin therapy, reduces cardiovascular events after recent acute coronary syndrome. However, the impact of ezetimibe on cardiovascular-related hospitalizations and associated costs is unknown.We used patient-level data from IMPROVE-IT (Improved Reduction Outcomes: Vytorin Efficacy International Trial) examine simvastatin-ezetimibe versus simvastatin-placebo related (excluding drug costs) over 7 years follow-up. Medicare Severity-Diagnosis Related Groups were...
The purpose of this study was to evaluate the economic impact Absorb bioresorbable vascular scaffold compared with Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention.The ABSORB III trial (Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease) demonstrated that noninferior respect target lesion failure at 1 year. Whether health care costs differ between and is unknown.We performed a prospective alongside trial, which intervention stable...
To assess whether survival rates for in-hospital cardiac arrest (IHCA) vary across hospitals depending on resuscitations are typically led by an attending physician, a physician trainee, or nonphysician.
Background Identifying actionable resuscitation practices that vary across hospitals could improve adherence to process measures or outcomes after in-hospital cardiac arrest (IHCA). We sought examine whether hospital debriefing frequency IHCA varies and which routinely perform have higher rates of process-of-care compliance survival. Methods conducted a nationwide survey in April 2018, were then linked data from the Get With The Guidelines-Resuscitation national registry for IHCA. Hospitals...
Abstract Background Renal-artery stenosis can be associated with difficult to control hypertension, although renal-artery stenting has not been shown improve clinical outcomes. Alternative antihypertensive medications could potentially result in quality of life benefits stenting. Methods and results We performed a pre-specified sub-study the CORAL trial—multicenter, randomized, open-label trial vs. medical therapy patients atherosclerotic stenosis. Longitudinal growth curve models were used...